Enanta Pharmaceuticals Inc ENTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENTA is a good fit for your portfolio.
News
-
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
-
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
-
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
-
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
-
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
-
Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial
Trading Information
- Previous Close Price
- $13.14
- Day Range
- $12.83–13.41
- 52-Week Range
- $8.08–22.13
- Bid/Ask
- $13.36 / $13.39
- Market Cap
- $283.59 Mil
- Volume/Avg
- 110,108 / 170,856
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 145
- Website
- https://www.enanta.com
Comparables
Valuation
Metric
|
ENTA
|
AVIR
|
INVA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 10.06 |
Price/Book Value | 1.68 | 0.55 | 1.46 |
Price/Sales | 3.80 | — | 4.48 |
Price/Cash Flow | — | — | 8.33 |
Price/Earnings
ENTA
AVIR
INVA
Financial Strength
Metric
|
ENTA
|
AVIR
|
INVA
|
---|---|---|---|
Quick Ratio | 6.23 | 13.11 | 8.51 |
Current Ratio | 6.43 | 13.28 | 10.42 |
Interest Coverage | −12.14 | — | 9.81 |
Quick Ratio
ENTA
AVIR
INVA
Profitability
Metric
|
ENTA
|
AVIR
|
INVA
|
---|---|---|---|
Return on Assets (Normalized) | −25.87% | −20.62% | 15.69% |
Return on Equity (Normalized) | −50.83% | −21.76% | 29.88% |
Return on Invested Capital (Normalized) | −46.23% | −25.76% | 17.71% |
Return on Assets
ENTA
AVIR
INVA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Jrxdgctzp | Gvzm | $624.9 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Wplnctswc | Lylzjqb | $121.4 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Jkzrsntfy | Cckcn | $112.8 Bil | |||
Moderna Inc
MRNA
| Rbzncghql | Cmn | $44.4 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Gzltbmbm | Chgqwp | $31.5 Bil | |||
argenx SE ADR
ARGX
| Ttykyhtv | Fjtk | $25.9 Bil | |||
BioNTech SE ADR
BNTX
| Sxslptbd | Tcy | $19.2 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Nlznjmzpt | Qrhbd | $15.4 Bil | |||
United Therapeutics Corp
UTHR
| Rtfjhff | Tlpn | $13.8 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Cdmymbkym | Nvprtv | $11.7 Bil |